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Abstract
Background: Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are key players in epigenetic
regulation of gene expression. Analgesic activity by HDAC inhibitors has been reported in different pain models
including inflammatory and neuropathic pain. These drugs interfere with gene expression through different
mechanisms including chromatin remodeling and/or activation of transcription factors. Among other targets,
HDAC inhibitors regulate metabotropic glutamate receptors type 2 (mGlu2) expression in central and peripheral
central nervous system. However whether inhibition of HAT activity also regulates mGlu2 expression has not
been reported.
Findings: Here we report that curcumin (CUR), a naturally occurring compound endowed with p300/CREB-binding
protein HAT inhibitory activity, is able to induce a drastic down-regulation of the mGlu2 receptor in the mouse spinal
cord after systemic administration together with a marked hypoacetylation of histones H3 and H4 in dorsal root ganglia
(DRG). Furthermore, the analgesic activity of the mGlu2/3 agonist, LY379268 is lost after a 3-day treatment with CUR.
Conversely the analgesic activity of LY379268 is potentiated in mice pretreated for 5 consecutive days with the HDAC
inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), known to induce mGlu2-upregulation.
Conclusions: Our results demonstrate that systemically injected CUR is able to inhibit H3 and H4 acetylation in the
DRG and to down-regulate mGlu2 receptors in the spinal cord. We also demonstrate that long term modification of
the mGlu2 expression affects the analgesic properties of the orthosteric mGlu2/3 agonist, LY379268. These data open
up the possibility that epigenetic modulators might be given in combination with “traditional” drugs in a context of a
multi target approach for a better analgesic efficacy.
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Findings
Background
Histone deacetylases (HDACs) and histone acetyltrans-
ferases (HATs) are two families of enzymes that regulate
the acetylation status of lysine residues of histone tails,
thus behaving as a chromatin modulators. The hyper- or
hypo-acetylation state of chromatin impacts on the acces-
sibility of specific DNA sequences to transcription factors
and other modulators of gene expression. Thus, HDAC or
HAT inhibitors act as epigenetic modulators able to
induce long-term changes in gene expression [1,2]. Beside
histones, HDACs and HATs also target non-histone pro-
teins and transcription factors therefore modulating the
expression of a number of receptors, ion channels and
other downstream targets [3]. HDAC inhibitors and
acetylating agents have been shown to induce analgesia in
different models of inflammatory pain [1,4-9] and to alle-
viate nerve injury-induced hypersensitivity [8-14]. Several
epigenetic mechanisms have been proposed to explain the
analgesic activity of HDAC inhibitors. We first reported
that an increased expression of the metabotropic glutam-
ate receptor type 2 (mGlu2) in the spinal cord and dorsal
root ganglia (DRG) is responsible for the analgesic effect
of two different HDAC inhibitors such as suberoylanilide
hydroxamic acid (SAHA) and N-(2-aminophenyl)-4-[N-
(pyridine-3-ylmethoxy-carbonyl)aminomethyl] benzamide
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(MS275) in the second phase of the formalin test [5]. The
mechanism underlying the mGlu2 overexpression induced
by HDAC inhibitors has been related to the activation of
the NF-κB pathway by an increased acetylation of the p65
subunit at lysine 310 (K310) [5,6].
With this study we sought to evaluate whether inhib-
ition of HAT activity might affect mGlu2 expression and
thus have an impact on mGlu2-mediated analgesia. To
test this hypothesis we used a naturally occurring com-
pound endowed with p300/CREB-binding protein (CBP)
histone HAT inhibitory activity, curcumin (CUR),
extracted from rhizomes of turmeric Curcuma longa
[15-17]. We also evaluated the analgesic effect of the
mGlu2/3 agonist, LY379268, in mice in which the expres-
sion of the mGlu2 receptor was epigenetically modulated.
Results and discussion
We examined the effect of repeated injection with the
naturally occurring p300/CBP HAT inhibitor, CUR, on
the mGlu2 expression level in the spinal cord. Chronic
administration of CUR at doses ranging from 50 to
300 mg/kg have been shown to be well tolerated in
behavioral studies [18]. Intraperitonally injected CUR
(100 mg/kg) is able to decrease histone acetylation in
the CNS only after inclusion in nanostructured lipid
carriers [17]. In this study we demonstrated that CUR
(100 mg/kg, ip) was able to significantly reduce the
mGlu2 receptor expression in the mouse spinal cord
after 24 hours from the injection with a lowest level
reached after 3 consecutive days of administration
(Figure 1). However no further reduction in mGlu2 re-
ceptor expression was observed after a more prolonged
treatment such as a 5-day treatment (data not shown).
Systemically injected, CUR was also able to induce a
significant H3 and H4 hypoacetylation in the DRG
(Figure 2A, 2B). Since mGlu2 receptors play an important
role in pain behavior and in the analgesic effects of
mGlu2/3 agonists [19] we next evaluated whether a 3-day
CUR administration has an impact on pain behavior in
the mouse formalin test and/or affects the analgesic activ-
ity of the mGlu2/3 agonist, LY379268. mGlu2/3 agonists
are known to induce analgesia in different pain models
including the formalin test [10,19-29]. Consistent with
data from literature, a single administration of LY379268
Figure 1 Expression of mGlu2 receptors in the mouse spinal cord after curcumin treatment. A single or repeated injections of CUR
(100 mg/kg, ip) decreased the expression of mGlu2 receptors in the lumbar segment of the spinal cord. Data are the means ± S.E.M. of 4 animals.
*p < 0.05 (Student’s t test) versus values obtained in animals treated with vehicle.
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(3 mg/kg, ip) 30 minutes before formalin injection, was
able to induce analgesia in the mouse formalin test
(Figure 3A-D). Also, to test the effect of a 3-day treatment
with CUR on the analgesic activity of LY379268 we
pretreated mice with CUR (100 mg/kg, ip) for three
consecutive days with the last injection 24 hours before
the formalin test and then mice received either saline or
LY379268 30 minute before the formalin injection. Al-
though CUR was able to induce mGlu2 downregulation,
mice receiving a 3-day pretreatment with CUR exhibited a
slight but not significant increase of pain behavior in the sec-
ond phase of the formalin test compared to saline-injected
mice (Figure 3A,B). However, under these conditions, the
analgesic effect of LY379268, was lost (Figure 3A,B).
We then moved to test whether repeated injection with
the HDAC inhibitor, SAHA, would affect the analgesic ac-
tivity of the mGlu2/3 agonist, LY379268. To address this
question we pretreated mice with SAHA (5 mg/Kg, sc) for
5 consecutive days. As previously shown [5], while a single
injection of SAHA is not analgesic and does not affect
mGlu2 receptor expression in the mouse spinal cord, a
5-day pretreatment is sufficient to upregulate mGlu2
receptors and to reduce the second phase of the mouse for-
malin test [5]. Here we show that, opposed to Curcumin,
when mice were pretreated with SAHA (5 mg/Kg, sc)
for 5 consecutive days with the last injection 24 hours
before the formalin injection the analgesic effect of
LY379268 (3 mg/kg, ip), acutely injected 30 minutes be-
fore formalin injection, was potentiated in the second
phase of the formalin test (Figure 3C,D).
Our data show that epigenetic modulation of mGlu2
receptors affects the analgesic activity of orthosteric
mGlu2/3 ligands. It has been shown that mGlu2 expression
is regulated by epigenetic mechanism in peripheral and
central nervous system regions including DRG, spinal cord
[5,9], and prefrontal cortex [30]. Particularly, pharmaco-
logical treatments leading to protein hyperacetylation, such
as HDAC inhibitors or L-acetylcarnitine, have been shown
to increase the expression of mGlu2 receptor both in
in vivo and in vitro experiments [5,6,9,10,30-32] and to in-
duce analgesia in the second phase of the mouse formalin
test [5,6]. However, no report indicates whether a decreased
protein acetylation level might influence the expression of
mGlu2 receptor and thus have an impact on mGlu2/3
agonist-induced analgesia. As a p300/CBP HAT inhibitor,
CUR can contribute to the regulation of gene expression
[15,16]. p300/CBP is ubiquitously expressed and plays an
important role in a wide range of biological responses
involved in inflammation, cancer and neurodegenerative
diseases [26,33,34]. Although CUR-induced p300/CBP
inhibition results in a consistent mGlu2 receptor downreg-
ulation, the lack of hyperalgesic activity of CUR might be
related to the lack of specificity of HAT inhibitors. A num-
ber of targets have been shown to be modulated by CUR,
many of which might impact pain behavior [27]. Based on
our previous works showing that HDAC inhibitor regulate
mGlu2 receptor expression via NF-κB activation [5,6], here
we focus on the ability of CUR to epigenetically downregu-
late mGlu2 receptor in DRG and thus to modulate mGlu2/
3 analgesic activity. Interestingly, CUR also inhibits NF-κB
activation and the expression of its target genes [35]. We
have previously shown that systemic administration of
CUR is not able to induce histone hypoacetylation in the
spinal cord unless CUR is included in a nanocarrier lipid
matrix [17]. This is consistent with the low bioavailability of
CUR because of its rapid metabolism and pharmacokinetic
Figure 2 Expression of acetyl-H3 and acetyl-H4 in the mouse dorsal root ganglia after a 3-day curcumin pretreatment. Repeated
injection of curcumin (100 mg/kg, ip, for three days) reduced the expression of acetyl-H3 and acetyl-H4 in the DRG. DRGs were dissected on the
third day, 24 hours after the last administration. A representative immunoblot of acetylated-H3 and acetylated-H4 in DRG extracts from mice
treated with curcumin is shown in (A) and (B) respectively. Densitometric analysis of acetyl-H3 and acetyl-H4 normalized by actin is shown. Data
are the means ± S.E.M. of 4 animals. *p < 0.05 (Student’s t test) versus values obtained in animals treated with vehicle.
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characteristics that do not allow the drug to reach high
concentration in the CNS [36]. In our study we show that
systemically injected CUR is able to induce H3 and H4
hypoacetylation in the DRG. Although CUR is not able to
induce hypoacetylation in the spinal cord after systemic in-
jection, the reduced acetylation observed in the DRG might
be explained by the lack of the blood brain barrier that in-
creases DRG neuron vulnerability compared to the central
nervous system. The effect of CUR in the DRG also ex-
plains the downregulation of mGlu2 receptors in the spinal
cord. In fact, mGlu2 receptors in the dorsal horn of the
spinal cord are presynaptically expressed in the primary
sensory afferents whose cell bodies are located in the DRG
[28]. the presynaptic localization of mGu2 receptors on
primary afferent neurons, together with the absence of
blood brain barrier in DRG also explain the effect of SAHA
on mGlu2 receptor expression in the spinal cord despite its
poor brain permeability [29]. The lack of analgesic effect in
the formalin test by the mGlu2/3 agonist LY379268 in
CUR-treated mice is consistent with our previous work
showing that LY379268 is not analgesic in mice lacking of
the mGlu2 receptors [19,37]. Recently, the role of p300 in
chronic pain has been investigated. Zhu and colleagues [38]
show that p300 is involved in the development of neuro-
pathic pain and that a reversal of hyperalgesia can be in-
duced by strategies that inhibit or down-regulate p300 in
the spinal cord. The authors showed that p300 is up-
regulated at day 14 after the induction of neuropathic pain
Figure 3 CUR and SAHA differently affect the analgesic efficacy of LY379268 in the mouse formalin test. (A, B) CUR-treated mice
(100 mg/kg, ip for three consecutive days) did not significantly differ from vehicle-treated mice. The acute administration of LY379268 (3 mg/kg,
i.p.) 30 minutes before formalin injection significantly reduced both phases in mice. A single administration of LY379268 (3 mg/kg, i.p.) 30 min
before formalin in CUR-pretreated mice failed to induce analgesia in both phases of the formalin test. (C, D) SAHA treated mice (5 mg/kg, sc, for
5 consecutive days) significantly reduced the licking behavior in the second phase of the formalin test. A single administration of LY379268
(3 mg/kg, i.p.) 30 minutes before formalin injection significantly reduced both phases in mice. The analgesic effect of LY378268 acutely injected
30 min before formalin was potentiated in SAHA-pretreated mice. Data represent the mean ± S.E.M. of 12 to 16 mice per group. *p < 0.05
(Two-way ANOVA + Bonferroni) versus the respective vehicle group, °p < 0.05 (Two-way ANOVA + Bonferroni) versus the corresponding group
treated with SAHA.
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with the chronic constriction injury of the sciatic nerve
model. Moreover, the inhibition of p300 HAT by intra-
thecal administration of a small molecule with p300 HAT
inhibitory activity, C646, or by down-regulating p300 with
specific small hairpin RNA (shRNA) suppress cyclooxy
genase-2 (COX-2) expression [38]. These data are not in
contrast with our result showing that the p300/CBP HAT
inhibitor, CUR, does not affect pain behavior in the forma-
lin test, since we have shown that, when systemically
injected, CUR affects histone acetylation in the DRG, but
not in the spinal cord [17]. Consistent with this hypothesis,
CUR has been shown to reduce the second phase of the
formalin test when intrathecally injected [39].
In this short report we show that a bidirectional
modulation of mGlu2 expression in the spinal cord in-
duced by repeated administration of so called “epigenetic
drugs”, such as HDACs or HATs inhibitors, can either




Adult (8–10 weeks) Wild type CD1 mice Were used in
this study. All mice were housed under a 12 h light/dark
cycle with free access to food and water. All mouse proto-
cols are in accordance with Institutional Animal Care and
Use Committee (IACUC) guidelines. All efforts were
made to minimize animal suffering and to reduce the
number of animals used.
Drugs
Curcumin (Sigma-Aldrich) was dissolved in normal saline
solution containing 0.05% dimethyl sulfoxide (DMSO), as
previously described [17]. Curcumin was administered to
CD1 mice at 100 mg/kg body weight intraperitoneally
(i.p.) once a day for three consecutive days with the last
injection 24 h before behavioral test. A vehicle solution
containing 0.05% DMSO was given as control for the
curcumin group. SAHA (Calbiochem) was dissolved in 5%
DMSO and injected at 5 mg/kg subcutaneously for 5
consecutive days with the last injection 24 h before behav-
ioral tests. LY379268 (Toscris) was acutely injected at
3 mg/Kg, sc 30 min before the formalin test. A vehicle




Formalin (5%, 10 μl; Sigma-Aldrich) was injected sub-
cutaneously into the plantar side of the right hind paw
as reported previously [5]. In the formalin test, the total
time spent licking or biting the injected hind paw was
recorded for each five-minute intervals for one hour
post injection. Formalin scores were separated into two
phases, phase I (0–10 min) and phase II (15–50 min). A
mean response was then calculated for each phase. All
tests were performed blind to treatment.
Immunoblotting
Tissues from the lumbar segment of the spinal cord or
DRG from L4–L5 were removed and homogenized. Ten
micrograms of total protein were separated by 10% SDS
polyacrylamide gel electrophoresis and electrophoretically
transferred onto protein-sensitive nitrocellulose mem-
branes (Criterion blotter; Bio-Rad Laboratories, Hercules,
CA). The membranes were blocked in Odyssey blocker
(LI-COR Biosciences, Lincoln, NE) for 1 h, and the follow-
ing primary antibodies were used: rabbit anti-acetyl H3
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit
Ac-Histone H4 (Lys 12) (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA); rabbit Ac-Histone H3 (Lys 18) (1:200,
Abcam); mouse anti actin (1:1000; Sigma Aldrich). Mouse
anti-metabotropic Glutamate Receptor 2 (1:500; Abcam).
Primary antibodies were incubated overnight at 4°C. The
following secondary antibodies were incubated for 1 h at
room temperature: goat anti-rabbit antibody labeled with
IRD800CW (LICOR) and goat anti-mouse antibody labeled
with Alexa Fluor 680 (Invitrogen, Carlsbad, CA). Proteins
were detected with the Odyssey Infrared Fluorescence
Imaging System (LI-COR).
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